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TET1/2/3 are methylcytosine dioxygenases that
regulate cytosine hydroxymethylation. Tet1/2 are
abundantly expressed in HSC/HPCs and are impli-
cated in hematological malignancies. Tet2 deletion
in mice causes myeloid malignancies, while Tet1-
nullmice develop B cell lymphoma after an extended
period of latency. Interestingly, TET1/2 are often
concomitantly downregulated in acute B-lympho-
cytic leukemia. Here,we investigated the overlapping
and non-redundant functions of Tet1/2 using Tet1/2
double-knockout (DKO) mice. DKO and Tet2/
HSC/HPCs show overlapping and unique 5hmC and
5mC profiles. DKO mice exhibit strikingly decreased
incidenceanddelayedonset ofmyeloidmalignancies
in comparison to Tet2/ mice and in contrast
develop lethal B cell malignancies. Transcriptome
analysis of DKO tumors reveals expression changes
in many genes dysregulated in human B cell malig-
nancies, including LMO2, BCL6, andMYC. These re-
sults highlight the critical roles of TET1/2 individually
and together in the pathogenesis of hematological
malignancies.
INTRODUCTION
The ten-eleven translocation (TET) family of proteins is
composed of three members, TET1, TET2, and TET3 (Iyer
et al., 2009; Tahiliani et al., 2009). They share a conserved1692 Cell Reports 13, 1692–1704, November 24, 2015 ª2015 The AuCys-rich domain and double-stranded beta helix domain (Iyer
et al., 2009). TETs exhibit their unique enzymatic function and
facilitate DNA demethylation, oxidizing 5-methylcytosine (5mC)
to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC),
and 5-carboxylcytosine (5caC) in a stepwise manner (He et al.,
2011; Ito et al., 2011; Tahiliani et al., 2009). TETs can thus act
as epigenetic regulators and modulate gene transcription and
cellular functions (Pastor et al., 2013).
Mutations and/or deletions of the TET2 gene have been re-
ported to frequently occur in multiple myeloid malignancies,
including approximately 30% of myelodysplastic syndromes
(MDS), 20% of myeloproliferative neoplasms (MPN), 17% of
de novo acute myeloid leukemias (AML), 30% of secondary
AMLs, and 50%–60% of chronic myelomonocytic leukemias
(CMMLs) (Delhommeau et al., 2009; Jankowska et al., 2009;
Langemeijer et al., 2009). TET2 mutations have also been found
in approximately 2% of Hodgkin’s lymphoma cases and 11.9%
of T cell lymphoma patients (Quivoron et al., 2011). In addition,
Musialik et al. recently showed that TET2 expression is signifi-
cantly lower in acute B-lymphocytic leukemia (B-ALL) patients
when compared to control CD19+ samples. TET1 was first iden-
tified as a fusion partner of the mixed lineage leukemia (MLL)
gene in AML patients carrying t(10,11)(q22;q23) (Ono et al.,
2002). Recently, TET1 was shown to be transcriptionally down-
regulated in human B cell non-Hodgkin lymphomas (B-NHL),
including diffuse large B cell lymphoma (DLBCL) and follicular
lymphoma (FL) (Cimmino et al., 2015). Huang et al. reported
that TET1 is significantly upregulated and plays an oncogenic
role in MLL-rearranged leukemia, rendering TET1 as a potential
target for treating this form of hematopoietic malignancy (Huang
et al., 2013). However, Cimmino et al. recently showed that dele-
tion of Tet1 promoted the development of B cell lymphoma inthors
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Figure 1. Analyses of TET1 and TET2 Gene Expression in Human
Acute B-Lymphocytic Leukemia Patients
qRT-PCR analysis of TET1 (A) and TET2 (B) expression in peripheral blood
(PB) mononuclear cells from B-ALL patients (n = 27) and PB CD19+ cells
from healthy controls (n = 9). Patients with concurrent TET1 and TET2
downregulation are marked with a blue dot (n = 9). The relative mRNA
expression of each TET gene was determined using GAPDH as internal cali-
brator. The mRNA expression levels are reported as relative expression
units to the respective TET expression in a B-ALL patient with themiddle range
TET1 or TET2 expression.mice (Cimmino et al., 2015). These studies indicate that TET1
may play an oncogenic or tumor suppressive role in a cell-
type-specific fashion.
Both Tet1 and Tet2 are abundantly expressed in hematopoiet-
ic stem/progenitor cells (HSC/HPCs) and differentiated lineages
such as B cells and myeloid cells (Huang et al., 2013; Li et al.,
2011; Moran-Crusio et al., 2011). Tet2 plays a prominent and
essential role in HSC self-renewal, proliferation, and differentia-
tion, and Tet2 loss leads to an increased HSC self-renewal and
skewed differentiation favoring monocytic lineage (Ko et al.,
2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al.,
2011). Furthermore, Tet2/mice develop myeloid malignancies
including CMML, MPN-like myeloid leukemia, and MDS (Li et al.,
2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). Tet2,
therefore, acts as a tumor suppressor in myelopoiesis.
Given the abundant expression of both Tet1 and Tet2 along
the HSC differentiation hierarchy, Tet1 and Tet2 can have
both non-redundant and overlapping functions in regulating
HSC maintenance, hematopoietic homeostasis, and leukemo-
genesis. Interestingly, TET1 and TET2 are often concomitantly
downregulated in B-ALL. Therefore, it is important to investigate
the effects of combined loss of Tet1/2 on the hematopoietic
phenotype and development of hematological malignancies
in vivo. Here, we report that combined deficiency of Tet1/2
causes mainly B cell malignancies in DKO mice with a strikingly
decreased frequency and delayed onset of myeloid malig-
nancies compared to Tet2/ mice. Tet2/ and DKO HSC/Cell RepHPCs displayed distinct DNA 5hmC/5mC signatures, which
does not correlate with gene expression alteration. Transcrip-
tome analysis of DKO tumors revealed altered expression in
many genes dysregulated in human B cell malignancy, including
LMO2, BCL6, andMYC. These findings provide a framework for
further studies on molecular mechanisms that critically link TET1
and TET2 in the pathogenesis of hematological malignancies.
RESULTS
TET1 and TET2AreOftenConcomitantly Downregulated
in Human Acute B-Lymphocytic Leukemia Patients
TET2 is frequently mutated in both myeloid and lymphoid malig-
nancies, whereas TET1mutations are rare. We first examined by
quantitative real-time PCR the mRNA expression of TET1 and
TET2 in peripheral blood (PB) mononuclear cells from a cohort
of B-ALL patients, and compared it with that of PB CD19+ B cells
from healthy controls. Downregulation of TET1 mRNA expres-
sion was observed in 21 of the 27 B-ALL patients as compared
to healthy controls (Figure 1A), while downregulation of TET2
was noted in nine of the 27 B-ALL patients (Figure 1B). Interest-
ingly, all of the nine B-ALL patients with TET2 downregulation
had concomitant TET1 downregulation (Figures 1A and 1B).
These data suggest that combined TET1 and TET2 loss may
play important roles in the pathogenesis of B cell malignancies
and prompted us to examine the hematological phenotype dis-
played in Tet1/2 DKO mice.
Tet1/2 DKO Mice Develop Lethal B Cell Malignancies
Analysis of hematological parameters on young wild-type (WT),
Tet1/, Tet2/, and DKO mice showed that up to 4 months
of age DKO mice do not exhibit signs of CMML development
that Tet2/ mice display at this age (Figure S1) (Li et al.,
2011). To determine whether DKO mice develop hematological
malignancies later in life, we aged a cohort of WT, Tet1/,
Tet2/, andDKOmice. Analysis of total blood counts and blood
smears of 12- to 15-month-old Tet2/ mice revealed features
that are consistent with development of myeloid malignancies.
Most of the aged Tet2/ mice displayed significantly higher
WBC counts (mainly caused by neutrophilia and monocytosis),
compared to age-matched WT mice (Figures 2A and 2B). The
blood cell counts of aged Tet1/ mice were comparable
to those of WT mice (Figure 2A). In contrast, 12 of the 19 aged
DKO mice exhibited increased WBC counts, with 11 caused by
marked lymphocytosis but normal monocyte and neutrophil
counts (Figures 2A and 2B). Only one of these DKO mice (G3-
21) displayed prominent neutrophilia and monocytosis but
normal lymphocyte count. Two of the 19 DKO (10.6%) and three
of the 14 Tet2/ (21.4%) mice were anemic, evidenced by
reduced RBC counts. PB smears from most of the DKO mice
showed absolute lymphocytosis with predominantly intermedi-
ate to large-sized lymphocytes containing a small amount of
cytoplasm and slightly irregular and dispersed nuclear chromatin
(Figure 2B). Interestingly, 68.4% of the DKOmice either became
moribund or died within 20 months of their life, whereas none of
the WT, 7.6% of Tet1/, and 90% of Tet2/ mice died at the
endpoint of our evaluation (Figure 2C; Table S1). Necropsy
of the moribund/deceased DKO mice revealed pronouncedorts 13, 1692–1704, November 24, 2015 ª2015 The Authors 1693
hepatosplenomegaly in all and enlarged lymph nodes in most of
the mice (Figure 2D; Table S1). Flow cytometric analyses on PB,
spleen, and BM cell preparations from the moribund/deceased
DKO mice revealed predominant proportions of B220+IgM+/low
CD43+CD19+ B-lymphocytes with high forward scatter (FSC) in
nine of the tenDKOmice, demonstrating a neoplastic monomor-
phic expansion of B cell origin (Figures 2E, S2A, and S2B;
Table S1). Furthermore, the neoplastic B-lymphocytes ex-
pressed CD71 in all and CD5 in two-thirds of the DKOmice (Fig-
ure S2B; Table S1). In each of the DKO mice with predominant
neoplastic B cells, the proportion of myeloid and T cells in the
PB, BM, and spleen were either decreased or comparable to
WT mice (Figure S2C), which is likely related to the predomi-
nance of B cell populations rather than a primary defect. Note
that in one moribund DKO animal (G3-21) with monocytosis/
neutrophilia, its BM and spleen cells showed predominant pro-
portions of CD11b+F4/80+Gr-1low monocytic cell populations
(Table S1), indicating CMML.
Examination of H&E-stained BM, spleen, liver, and lymph
node sections and May-Giemsa-stained cytospin preparations
of BM and spleen cells from the moribund/deceased DKO
mice revealed extensive infiltration with intermediate to large-
sized immature-appearing lymphocytes with large nuclei and
small amount of cytoplasm, slightly irregular nuclei and
dispersed nuclear chromatin (Figures 2F and S2D). BM showed
diffuse neoplastic lymphoid infiltration with decreased normal tri-
lineage hematopoiesis (Figure 2F). The normal architecture of
spleen and lymph nodes was effaced and replaced by diffuse
atypical lymphoid infiltrates (Figure 2F). Both red and white
pulp of the spleen were involved. The liver displayed nodular
and sinusoidal lymphoid infiltration, which was also confirmed
by immunostaining with anti-B220 and anti-CD43 antibodies
(Figures 2F and 2G). Furthermore, to determine whether these
monotypic expansions/infiltrations were clonal, PCR analysis
of immunoglobulin H (IgH) D-J rearrangements was performed.
Clonal gene rearrangements were detected for IgD-J junctions
in five of six mice tested. Splenic B cells from three DKO mice
showed monoclonal Ig rearrangements. Two mice demon-
strated biclonal Ig rearrangements. These Ig gene rearrange-
ment assays revealed that the splenic B220+ cells from each of
these DKO mice with monomorphic B cell expansions/infiltra-
tions were clonal, while B220+ cells from the DKO case with
CMML or WT displayed oligoclonal patterns (Figure 2H). Collec-
tively, the majority of these aged DKO mice developed B cell
malignancy, with features most closely resembling human
B-ALL (Table S1).
B Cell Malignancy in DKOMice Is Transplantable to
Secondary Recipients
To evaluate the malignant nature of the abnormally infiltrated
B-lymphocytes in DKO mice, spleen cells from a moribund
DKO (G2-53) and a WT mice were transplanted into sublethally
irradiated WT recipients (Figure S3A). None of the recipients
receiving WT spleen cells developed pathology or gross evi-
dence of disease within 4 months of transplantation (Figures
3A–3D). In contrast, all of the mice receiving DKO spleen cells
developed diseases with similar characteristics as those
observed in the primary mouse including elevated WBC counts,1694 Cell Reports 13, 1692–1704, November 24, 2015 ª2015 The Aulymphocytosis, splenomegaly, enlarged lymph nodes, and death
(Figures 3A, 3B, S3B, and S3C). Flow cytometric analysis
and histological and cytospin examination of PB, spleen, BM,
liver, lymph node, lung, and kidney cells of the recipients re-
vealed predominant infiltration of a uniform B cell population
(high FSC, B220+CD19+IgM+/lowCD43+CD5+CD71+) similar to
that observed in the primary DKO mouse (Figures 3C, 3D,
S3D, and S3E; data not shown). These data demonstrate that
the Tet1/2-deletion-induced B cell malignancy is transplantable,
suggesting a malignant and neoplastic nature of the infiltrated B
cells in DKO mice.
In addition, long-term observation of a cohort of Tet1+/;
Tet2/ mice (n = 15) showed that Tet1+/;Tet2/ mice have
an improved survival rate compared to Tet2/mice, but a com-
parable survival rate compared to DKO mice (Figure S2E; Table
S2). Interestingly, analysis of nine moribund/deceased Tet1+/;
Tet2/ mice demonstrate that seven of nine developed B cell
malignancy (B-ALL) and two of nine developed myeloid malig-
nancies (Figure S2F; Table S2). Our long-term observation of
196 Tet2/ mice demonstrate that 93% of Tet2/ mice
developed myeloid malignancies and only 4% developed B
cell malignancies (Figure S2F; our unpublished data). These
data indicate that Tet1 loss modulates Tet2-deletion-mediated
disease phenotype in mice, not only decreasing the incidence
and delaying the onset of myeloid malignancies, but also pro-
moting the pathogenesis of B cell malignancies.
Deletion of Tet1/2 Increases CLP/BLP Compartment
and Affects B Cell Development in Mice
To explore the cellular mechanisms by which deletion of Tet1/2
causes high frequency of B cell malignancies but low frequency
of myeloid malignancies, we analyzed HSC, myeloid, and
lymphoid progenitors and various maturation stages of B cell
populations in the BMof 5- to 7-week-oldDKOmice prior to their
development of hematological malignancies. The proportion of
LSK cells and each of the myeloid progenitors (CMP, GMP, and
MEP) was comparable to WT, Tet1/, and DKO mice, whereas
LSK and GMP cell populations were significantly increased in
Tet2/mice (Figures 4A and 4B; data not shown). Similar results
were obtained with conditional MxCre-mediated Tet1 and/or
Tet2 deletion in adult mice (Figures S4 and S5). Tet2f/f;MxCre
mice had increased LSK and GMP cell populations compared
to that of Tet1f/f;Tet2f/f;MxCre, Tet1f/f;MxCre and Tet1f/f;Tet2f/f
mice 5–6 weeks after pI:pC injection (Figures S5A–S5D).
We also assessed the replating potential of purified LSK cells
from 5- to 7-week-old WT, Tet1/, Tet2/, and DKO mice
by in vitro myeloid colony formation assays. A significant in-
crease in colony formation was observed for Tet2/ LSK cell
cultures in each round of replating, while Tet1/ and DKO
LSK cell cultures exhibited a moderate increase in the number
of colonies at P2, but not P3 and P4 (Figure 4C). Furthermore,
re-introduction of WT Tet1, but not catalytic domain inactive
mutant Tet1, into DKO LSK cells significantly increased their
replating potential at P2-P4 (Figures S5E and S5F). These data
suggest that Tet1 loss abrogated the Tet2-deletion-caused
LSK pool increment in vivo and their hyper-replating potential
in vitro. In addition, the catalytic activity of Tet1 is likely required
for Tet2 loss-induced hyper-replating potential in HSC/HPCs.thors
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Figure 2. Most of the DKO Mice Developed Lethal B-Lymphoid Malignancies
(A) Most of the agedDKOmice exhibited elevatedWBC and lymphocyte counts. WBC, neutrophil, monocyte, lymphocyte, and RBC counts were performed with
12- to 15-month-old DKO mice (n = 19) and age-matched WT (n = 13), Tet1/ (n = 12), and Tet2/ (n = 14) mice. *p < 0.05, **p < 0.01, ***p < 0.001.
(B) May-Giemsa-stained PB smears prepared from a representative moribund DKO mouse and age-matched WT, Tet1/ and Tet2/ mice. Bar, 20 mm.
(C) Kaplan-Meier survival curve of WT (n = 25), Tet1/ (n = 13), Tet2/ (n = 20), and DKO (n = 19) mice up to 650 days.
(D) The gross morphologies of spleen, liver, and lymph nodes from a representative moribund DKO and an age-matched WT mouse.
(E) Flow cytometric analysis of B cell lineage (B220/IgM) in PB, BM, and spleen of representativemoribundDKO (#G3-53 and #G2-53) and age-matchedWTmice.
The numbers indicate the percentages of cells in each cell population.
(legend continued on next page)
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Figure 3. The B Cell Malignancy in DKO
Mice Is Transplantable to Secondary
Recipients
(A) Kaplan-Meier survival curve of sub-lethally
irradiated recipients (six mice/donor) transplanted
with spleen cells (1 3 106) from a WT mouse or a
DKO mouse with B cell malignancy (G2-53).
(B–D) May-Giemsa-stained PB smear (B), flow
cytometric analyses on B cell lineage (C), and
H&E-stained histological sections (D, bar: 100 mm)
of femurs, spleen, liver, lymph node, kidney, and
lung from a representative recipient mouse
receiving spleen cells from a WT mouse or a DKO
mouse with B cell malignancy. Neoplastic lym-
phocytic infiltrates were identified in each of the
organs. Infiltrating patterns and cell morphology
were similar to those observed in the donor DKO
mice. These data demonstrate that the recipients
receiving spleen cells from the DKOmouse with B
cell malignancy developed a disease similar to
their donor mouse.Interestingly, a significantly increased frequency of common
lymphoid progenitors (CLPs) and B-lymphocyte progenitors
(BLP) is observed inDKOmice (5–7 weeks old), whereas compa-
rable CLP and BLP frequencies are seen in Tet1/, Tet2/,
and WT mice (Figures 4D–4F). In addition, when BM cells of
young WT, Tet1/, Tet2/, and DKO mice are examined for
their Pro-, Pre-, Immature-, and Mature-B cell populations,
DKO mice show significantly higher frequencies of Pro-, Pre-,
and Immature-B cells, but not mature-B cells, whereas, Tet1/
mice showhigher frequencies of Immature-B cells in comparison
to WT control mice (Figures 4G and 4H). Frequencies for each B
cell population is comparable or slightly decreased in Tet2/
mice in comparison to WT mice (Figures 4G and 4H), which
might be related to an increased Gr1/Mac1 cell population in
their BM. Consistently, B cell colony formation assay shows
significantly increased B cell colonies in the BM of DKO mice
compared to Tet1/, Tet2/, and WT mice (Figure 4I). A mod-
erate increase in B cell colony formation is also seen in Tet1/
and Tet2/mice compared toWT controls (Figure 4I). These re-
sults indicate that deletion of both Tet1/2 results in increased
CLP, BLP, and Pro-/Pre-/Immature-B cell populations in vivo(F) H&E-stained histological sections of femurs, spleen, liver, and lymph node (bar, 100 mm) from representa
matched WT mice.
(G) Liver sections from a representative moribund DKO (#G3-53) and WT mouse were immunostained using
(H) The D-J rearrangement of the IgH gene in splenic cells from DKO (n = 6) and WT mice.
1696 Cell Reports 13, 1692–1704, November 24, 2015 ª2015 The Authors(Figure 4J), which might predispose and/
or facilitate the development of B cell
malignancies.
Tet1/2-Deficient HSCs Exhibit an
Increased Short-Term, but Not
Long-Term, Hematopoietic
Repopulating Capacity
To determine whether deletion of Tet1/2
affects HSC activity in a cell intrinsicmanner in vivo, we performed a competitive BM reconstitution
assay by transplanting total CD45.2+ nucleated BM cells
(1 3 106) from 6- to 7-week-old Tet1f/f;Tet2f/f, Tet2f/f;
MxCre, or Tet1f/f;Tet2f/f;MxCremice along with an equal number
of WT CD45.1+ BM cells, into lethally irradiated F1 recipient mice
(Figure 5A). Four weeks after transplantation, the recipients were
assessed for CD45.2/CD45.1 chimeras in their PB by FACS anal-
ysis and then were induced for Tet1 and/or Tet2 deletion by
pI:pC injections. The contribution of CD45.1+ versus CD45.2+
cells in the PB was monitored every 4 weeks for 28 weeks after
pI:pC injections. CD45.2+ Tet1f/f;Tet2f/f cell chimeras remained
around 50%, whereas there was a steady increase in the
CD45.2+ Tet2f/f;MxCre cell chimeras that reached over 70% at
28 weeks. Interestingly, Tet1f/f;Tet2f/f;MxCre cell chimeras
increased to 60% during the first 16 weeks and then slightly
declined with no significant differences compared to Tet1f/f;
Tet2f/f CD45.2+ cell chimeras at 24 and 28 weeks. The Tet1f/f;
Tet2f/f;MxCre cell chimeras were significantly smaller than that
of Tet2f/f;MxCre cells after 20 weeks (Figures 5B and 5C).
Furthermore, Tet2f/f;MxCre, but not Tet1f/f;Tet2f/f;MxCre BM
cells contributed to a greater proportion of Gr1/Mac1tive moribund DKO (#G3-53 and #G2-53) and age-
anti-B220 or CD43 antibodies.
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Figure 4. Frequencies of HSC, Myeloid, and Lymphoid Progenitor Compartments, as well as Various B Cell Sub-populations in DKO Mice
(A)FlowcytometricanalysisofSca-1+c-Kit+andSca-1-c-Kit+cell populations in the totalBMcellsof representativeWT,Tet1/,Tet2/, andDKOmice (7weeksold).
(B) Quantitation of the percentage of Sca-1+c-Kit+ cells in the BM of each mouse genotype (mean ± SD, four to five mice/genotype).
(C) Colony-formation assay of LSK cells sorted from each genotype of BM cells inmethylcellulosemedium (500 cells/plate). Colonieswere passaged every 7 days
for three sequential platings (P1-4). Data are representative of three experiments.
(D) Flow cytometric analysis of common lymphoid progenitors (CLP, LinIL-7R+CD135+c-kitlowSca-1low) and B-lymphocyte progenitors (BLP, LinIL-
7R+CD135+Ly6D+c-kitlowSca-1low) in the BM of representative WT and DKO mice.
(E and F) Quantitation of the percentage of CLP (E) and BLP (F) in the total BM cells of each mouse genotype (mean ± SD, five to six mice/genotype).
(G) Flow cytometric analysis of Pro-B (B220+IgMCD19+CD43+), Pre-B (B220+IgMCD19+CD43), Immature-B (B220+IgM+), and Mature-B (B220+IgMlow) cell
populations in the BM cells of representative WT, Tet1/, Tet2/, and DKO mice (7 weeks old).
(H) Quantitation of the percentage of Pro-B, Pre-B, Immature-B, andMature-B cells in the total BM cells of each genotype of mice (mean ±SD, four to sevenmice/
genotype).
(legend continued on next page)
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granulocytic/monocytic cells and a smaller proportion of B220+
B cells in the recipient BM compared to controls (Figure 5D).
Consistent with PB, at 24 weeks after pI:pC injections, CD45.2
chimeras in the BM was also significantly higher in Tet2f/f;MxCre
BM transplants than Tet1f/f;Tet2f/f;MxCre or Tet1f/f;Tet2f/f BM
transplants (Figures 5E and 5F). Furthermore, within the
CD45.2+ BM cell populations, the frequencies of LSK and
GMP, but not CLP were increased in Tet2f/f;MxCre BM trans-
plants, whereas the frequency of CLP, but not LSK and GMP,
was increased in Tet1f/f;Tet2f/f;MxCre BM transplants as
compared to the control Tet1f/f;Tet2f/f BM transplants (Figures
5G–5I). These data suggest that Tet1/2 deletion in HSC/HPCs
moderately increases their short-term, but not long-term repo-
pulating capacity while promoting the CLP expansion. The
data also confirm previous observations that Tet2-deficient
HSCs exhibit an enhanced HSC activity and skewed differentia-
tion toward granulocytic/monocytic lineage.
In addition, three of the five mice receiving Tet2f/f;MxCre BM
cells hadmoderatemonocytosis and splenomegaly 24weeks af-
ter pI:pC injections (Figure 5J; data not shown), reminiscent of
the CMML phenotype displayed in Tet2/ mice. Furthermore,
two of the five mice receiving Tet1f/f;Tet2f/f;MxCre BM cells
had mild lymphocytosis and splenomegaly (Figure 5I; data not
shown), reminiscent of the B cell malignancy phenotype dis-
played in DKO mice. None of the mice receiving Tet1f/f;Tet2f/f
BM cells developed any signs of hematological malignancies.
These data suggest that the Tet1/2-deletion-induced phenotype
is likely cell autonomous.
Tet2/ and DKO LK Cells Display Distinct DNA
Methylation/Hydroxymethylation Signatures
Given the role of Tet proteins in 5mC oxidation, we employed a
previously established chemical labeling and affinity purification
method coupled with high-throughput sequencing (hMe-Seal) to
profile the genome-wide distribution of 5hmC. We also used
methylated DNA immunoprecipitation (MeDIP) coupled with
high-throughput sequencing (MeDIP-seq) to profile 5mC using
BM LK cells purified from young WT, Tet2/, and DKO mice
(5–8 weeks old). The loss of Tet2 or Tet1/2 leads to genome-
wide alterations of both 5mC and 5hmC (Figure 6A). We
observed significant overlap in differential hydroxymethylated
regions (DhMRs) or differential methylated regions (DMRs) be-
tween the two genotypes of LK cells (Figures 6B and S6A).
Intriguingly, the overlap between DhMRs and DMRs within
each genotype of LK cells was minimal, indicating that DhMRs
and DMRs might represent distinct loci with altered epigenetic
modifications under these conditions (Figures 6C and S6B).
To further explore molecular mechanisms underlying pheno-
types associated with these twomutant lines of mice, we applied
RNA sequencing (RNA-seq) to the LK cells from young Tet2/
and DKO mice that we used for epigenomic analyses. We pri-
marily focused on 654 genes that are known to be involved in(I) Pre-B colony-formation assays of BM cells from each mouse genotype. Colon
experiments.
(J) Schematic overview of the effects of Tet1 and/or Tet2 deletion on B cell deve
*p < 0.05, **p < 0.01, ***p < 0.001.
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leukemogenesis, based on previously published studies (Ab-
del-Wahab et al., 2013; Chambers et al., 2007; Shlush et al.,
2014). By overlappingwith the DhMRs or DMRs identified above,
we observed a significant number of these genes with altered
5hmC or 5mC modifications (Figures 6D and S6C–S6E). How-
ever, we did not observe significant expression changes in these
genes in either Tet2/ or DKO LK cells, and there was no clear
correlation between gene expression changes and the 5hmC/
5mC alteration (Figures 6E and 6F). This is consistent with previ-
ous findings that no direct correlation is observed between gene
expression alteration and 5hmC changes in mouse ES cells (Ficz
et al., 2011; Pastor et al., 2011; Williams et al., 2011). These ob-
servations suggest the roles of distinct cytosine modifications
(particularly 5hmC) could play in marking specific genes, which
may enable cells to respond to additional stimuli to subsequently
altering gene expression.
Altered Expression of Genes Implicated in Human B Cell
Malignancies in the B-ALL DKO B220+ Cells
Next, we performed RNA-seq to identify the dysregulated genes
in preleukemic andB-ALLDKOB220+cells. B220+ cellswere iso-
lated from the spleen cells of B-ALLDKOmice, age-matchedWT,
and pre-leukemic DKO mice. RNA-seq analysis of preleukemic
DKO B220+ cells identified a pool of dysregulated genes,
compared toWTB220+cells,which are implicated inBcell devel-
opment such as Sox4, Ets2, and Irf4 (Mallampati et al., 2014; Si-
monetti et al., 2013; Yoshimatsu et al., 2011), and consistent with
the observation that impaired B cell development occurs in these
DKO mice (Figure 7A). Moreover, analysis of the RNA-seq data
identified a panel of differentially expressed genes in B-ALL
DKO B220+ cells compared to WT or pre-leukemic DKO B220+
cells. When compared to pre-leukemic DKO B220+ cells, 294
genes were upregulated and 205 genes were downregulated in
B-ALL DKO B220+ cells (false discovery rate [FDR] <0.05). The
significantly altered genes in B-ALL DKO B220+ cells included
many dysregulated genes in human B cell malignancy such as
Lmo2, Bcl6, Myc, Pten, and Blk (Natkunam et al., 2007; Ott
et al., 2013; Pfeifer et al., 2013), further validating B cell malig-
nancy occurring in these B-ALL DKOmice (Figure 7B).
We then integrated the previously published TET1 and TET2
chromatin immunoprecipitation sequencing (ChIP-seq) data
with our RNA-seq data to search for known TET1 target genes
(Williams et al., 2011) and TET2 target genes (Deplus et al.,
2013) within the significantly dysregulated genes in B-ALL DKO
B220+ cells. Interestingly, nearly 40% of these dysregulated
genes were direct targets of TET1 (such as Jun, Myc, and
Lmo2), and 10% were direct targets of TET2 (such as Pbx3,
Rras2, and Flt3) (Figure 7C). These data suggest that Tet1 and/
or Tet2 are capable of regulating the expression of these
genes in the transformed B-ALL DKO B220+ cells, and Tet1
seems more capable of controlling its target gene expressionies were scored after 12–14 days of culture. Data are representative of three
lopment/maturation.
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Figure 5. Hematopoietic Repopulating Capacity of DKO HSCs
(A) Schematic depiction of the competitive transplantation scheme. CD45.2+ BM cells from Tet1f/f;Tet2f/f, Tet2f/f;MxCre, and Tet1f/f;Tet2f/f;MxCre mice were
mixedwith CD45.1+ competitor cells at a ratio of 1:1 (13 106 cells each) and transplanted into lethally irradiated F1 recipients. Recipients were injectedwith pI:pC
4 weeks after transplantation to induce MxCre-mediated Tet1/2 deletion in the CD45.2+ donor cells.
(B) The kinetics of the CD45.2+ cell chimerism in the PB of mice receiving each genotype of BM cells. Data are shown as mean ± SD from four to seven animals/
genotype.
(C) Flow cytometric analysis of PB cells from representative recipients of each group at 0 or 24 weeks after pI:pC injection.
(D) The lineage distributionwithin thePBCD45.2+ cells of each group of recipients 24weeks afterpI:pC injection (mean±SD from four to seven animals/genotype).
(E and F) The CD45.2+ cell chimerism in the BM of mice receiving each genotype of BM cells 24 weeks after pI:pC injection (mean ± SD, three to five animals/
genotype).
(legend continued on next page)
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Figure 6. Distinct DhMRs/DMRs and Their
Lack of Correlation with Gene Expression
in Tet2/ and DKO LK Cells
LK cells were sorted from the BM of WT, Tet2/,
and DKO mice (5–8 weeks old) and were analyzed
for their 5mC and 5hmC profiling.
(A) Dynamic change of normalized 5hmC/5mC read
counts ratio between Mutant (Tet2/ and DKO)
and WT cells in genome-wide DhMRs/DMRs.
Chromosome circular map shows genome-wide
dynamic change of normalized 5hmC/5mC read
counts ratio between Mutant and WT cells in
genome-wide DhMRs/DMRs. The outer track rep-
resents the normalized 5hmC read counts ratio
between Mutant and WT cells in DhMRs. The inner
track represents the normalized 5mC read counts
ratio between Mutant and WT cells in DMRs.
The orange color bar represents the normalized
5hmC/5mC read counts ratio in WT-specific
DhMRs/DMRs. The green color bar represents
the normalized 5hmC/5mC read counts ratio in
Mutant-specific DhMRs/DMRs.
(B) Significant overlap between DhMRs of Tet2/
and DKO LK cells. Venn diagram shows a signifi-
cant overlap between the DhMRs identified in
DKO versus WT cells and the DhMRs identified in
Tet2/ versus WT cells.
(C) Lack of overlap between DhMRs and DMRs
for DKO LK cells. Venn diagram shows a lack of
overlap between DhMRs and DMRs identified in
DKO versus WT cells.
(D) Venn diagram shows the overlap between
the HSC/leukemogenesis related gene bodies and
DhMRs identified in DKO versus WT. A significant
250 out of 654 HSC/leukemogenesis related genes
are overlapped with the DhMRs.
(E) The ratio of FPKM value of gene expression
between Mutant (Tet2/, DKO) and WT is plotted
against the ratio of normalized 5hmC read counts
between Mutant (Tet2/, DKO) and WT. The lack
of linear trend and significant deviation from the
diagonal line suggest a lack of correlation between
gene expression and 5hmC changes between
Mutant (Tet2/, DKO) and WT.
(F) The ratio of FPKM value of gene expression
between Mutant (Tet2/, DKO) and WT is plotted
against the ratio of normalized 5mC read counts between Mutant (Tet2/, DKO) and WT. The lack of linear trend and significant deviation from the diagonal line
suggest a lack of correlation between gene expression and 5hmC changes between Mutant (Tet2/, DKO) and WT.compared to Tet2. These data also suggest that altered genes in
B-ALL DKO B220+ cells are largely a direct result of combined
Tet1/2 loss.
DISCUSSION
TET1/2/3 promote DNA demethylation by catalyzing conversion
of 5mC primarily to 5hmC as well as 5-fC and 5-caC (He et al.,
2011; Ito et al., 2011; Tahiliani et al., 2009). Previous work has(G–I) Flow cytometric analysis of LSK (G), GMP/MEP/CMP (H), and CLP (I) freque
pI:pC injection representative.
(J) Spleen size of representative mice receiving Tet1f/f;Tet2f/f, Tet2f/f;MxCre, or T
*p < 0.05, **p < 0.01, ***p < 0.001.
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in myeloid malignancies (Delhommeau et al., 2009; Jankowska
et al., 2009; Langemeijer et al., 2009), in which TET2 functions
as a critical tumor suppressor (Li et al., 2011; Moran-Crusio
et al., 2011; Quivoron et al., 2011). Somatic TET2 mutations
also occur in T cell lymphoma (such as angioimmunoblastic
T lymphomas, 33%) and B-NHL (such as DLBCL, 12%; and
mantle cell lymphoma, 4%). Besides loss-of-function mutations
and deletions of TET2, TET2 inactivation or haploinsufficiencyncies within the BM CD45.2+ cells of each group of recipients 24 weeks after
et1f/f;Tet2f/f;MxCre BM cells 24 weeks after pI:pC injection.
thors
A B
C
Figure 7. B-ALL DKO B220+ Cells Had Altered Expression of Genes Implicated in Human B Cell Malignancies
(A) Heatmap of differentially expressed genes implicated in B cell development in preleukemic DKO B220+ cells as compared to WT B220+ cells (FDR <0.05, fold
change >2, Log transformed data are presented).
(B) Heatmap of differentially expressed genes in B-ALL DKO B220+ cells that are dysregulated in human B cell malignancies as compared to preleukemic DKO
B220+ cells (FDR <0.05, fold change > 2, Log transformed data are presented).
(C) Pie chart depicting the overlap of TET1-bound genes and TET2-bound genes within differentially expressed genes in B-ALLDKO B220+ cells as compared to
preleukemic DKO B220+ cells. See Table S4 for a full list of differentially expressed genes and Table S5 for overlapping genes from RNA-seq and TET1/TET2
ChIP-seq data.could result by other means such as gene downregulation.
Indeed, TET2 mRNA expression level is significantly decreased
in B-ALL compared to normal controls (Musialik et al., 2014).
Our data show that TET1 and TET2 are often concomitantly
downregulated in B-ALL patients. Recently, TET1 was shown
to be transcriptionally downregulated in B-NHL (DLBCL and
FL) (Cimmino et al., 2015). Given the frequency of TET2 muta-
tions in these patients, TET1 and TET2 are likely simultaneouslyCell Repinactivated in some cases of B-NHL. Although the definitive
function of TET1 in leukemogenesis remains to be determined,
a recent study has implicated loss of Tet1 in onset of B cell
lymphoma late in life (Cimmino et al., 2015). Nonetheless, Tet1
has also been implicated in an essential oncogenic role in
MLL-rearranged leukemia (Huang et al., 2013). The seemingly
opposite function of TET1 and TET2 in leukemogenesis and their
combined inactivation in B cell malignancy pose a challenge toorts 13, 1692–1704, November 24, 2015 ª2015 The Authors 1701
the investigation of their overlapping and non-redundant roles in
hematopoietic regulation and pathogenesis of hematological
malignancies.
The generation of both germline and conditional Tet1/2 DKO
mice has allowed us to gain valuable information toward ad-
dressing this important question and to determining the in vivo
consequences of both TET1/2 loss in hematopoiesis and hema-
tological malignancies. Our findings can be summarized as fol-
lows: (1) unlike Tet2 deletion, deficiency of Tet1/2 does not cause
an increased HSC pool in vivo and Tet1/2-deficient HSCs do not
possess an increased long-term repopulating capability and
skewed monocytic differentiation; (2) Tet1 loss dramatically
decreases the incidence, and markedly delays the onset of
Tet2-deletion-related myeloid malignancies; (3) deletion of both
Tet1/2 but not either in mice leads to increased CLP/BLP/Pro-
B/Pre-B/Immature-B cell populations and results in the develop-
ment of predominantly B-ALL; (4) Tet2/ and DKO LK cells
display distinct DNA methylation and hydroxymethylation signa-
tures; however, no correlation between gene expression and
DhMRs or DMRs is observed in both Tet2/ and DKO HSC/
HPCs; (5) transcriptome analyses of B-ALL DKO B220+ cells
identify alteration of genes that are dysregulated in human B
cell malignancies such as Lmo2, Bcl6, Myc, Pten, and Blk.
Although TET2 is frequently mutated in T cell malignancies like
angioimmunoblastic T lymphomas and peripheral T cell lym-
phoma (Sakata-Yanagimoto et al., 2014), and a fraction of
Tet2/ mice develop T cell malignancies (our unpublished
data), none of the DKO mice we analyzed developed T cell ma-
lignancy, suggesting a low incidence of T cell malignancy in
these mice. Future studies are required to determine the fre-
quency of T cell malignancy in DKO mice.
Recent genome-wide profiling of 5mC distribution in murine
HSC/HPCs highlights the significance of dynamic changes in
DNA methylation (Bock et al., 2012; Sun et al., 2014), while little
is known about 5hmC distribution in HSC/HPCs. Understanding
the biological significance of 5mC and 5hmC dynamics and their
relevance to TET1 and TET2 enzymes in HSC/HPCs is important.
In this study, we demonstrate that the loss of Tet2 or Tet1/2 leads
to genome-wide alterations of both 5mC and 5hmC. The signif-
icant amount of overlap of DhMRs or DMRs in LK cells between
Tet2/ and DKOmice represents the impact of Tet2 loss on the
genome of these cells. The small amount of overlap between
DhMRs and DMRswithin each genotype of LK cells is surprising,
but these results suggest that decreased-5hmC does not neces-
sarily result in increased-5mC in a specific locus of genome. It
will be very informative to map in these cells, 5fC and 5caC
genomic profiles simultaneously to determine their overlap with
5hmC or 5mC changes in the genome. As well, we observed
no correlation between gene expression and DhMRs or DMRs
in these LK cells that were isolated from pre-leukemic Tet2/
or DKOmice. Similar observations have been reported in mouse
ES cells (Ficz et al., 2011; Pastor et al., 2011; Williams et al.,
2011). These observations suggest that distinct cytosine
modifications (particularly 5hmC) mark specific genes in Tet2/
or DKO LK cells without altering their expression. Such could
work together with other genomic insults to alter gene expres-
sion. Indeed, the global transcriptome changed dramatically in
transformed B-ALLDKO tumor cells, andmost of these dysregu-1702 Cell Reports 13, 1692–1704, November 24, 2015 ª2015 The Aulated genes are direct targets of Tet1 or Tet2. A recent study has
shown that Tet2 loss cooperates with AML1-ETO oncogene to
promote DNA hypermethylation on enhancers (leading to the
loss of enhancer activity), resulting in lowered gene expression
(Rasmussen et al., 2015), while Tet2 loss alone is likely unable
to achieve this effect. Another recent study has shown that com-
bined Tet2 loss and Flt3 mutation alter DNA methylation and
gene expression in LSK cells, but not with either mutation alone,
and similar results are seen in human AML patients with com-
bined TET2 and FLT3 mutations (Shih et al., 2015).
These findings have several layers of implications: (1) they
highlight the critical roles of each of the enzymes and the
possible lines of communication between Tet1 and Tet2 in ho-
meostasis of hematopoiesis and pathogenesis of hematological
malignancies; (2) despite their similar catalytic activities in oxidi-
zation of 5mC, Tet1 is required for the Tet2-deletion-mediated
HSC dysregulation, myeloid skewing, and myeloid malignancy
development; TET1 therefore, likely plays a distinct role in
myeloid leukemogenesis in the context of TET2 loss; (3) Tet1
and Tet2 seem to have overlapping roles in B cell develop-
ment/tumorigenesis, where loss of Tet1 alone causes B cell ma-
lignancies and loss of both enzymes accelerates pathogenesis
of B cell malignancies. This study expands upon our previous
work that implicated Tet2 in myeloid malignancies (Li et al.,
2011) and Tet1 in lymphoid malignancies (Cimmino et al.,
2015). Our present studies suggest a novel role for Tet1 in
Tet2-loss-mediated leukemogenesis as such making it a poten-
tial target for therapeutic intervention in myeloid malignancy pa-
tients. Moreover, it reveals that combined loss of Tet1/2 in mice
induces B cell malignancies with a long latency. However, early
changes in DNA 5hmC/5mC, CLP/BLP pool, and B cell develop-
ment precede the development of disease. Whether Tet1/2 loss
promotes changes in chromatin accessibility that facilitates
acquisition of additional mutations requires further investigation.
In summary, the studies presented here identify overlapping,
non-redundant, and even opposite functions for Tet1 and Tet2
in hematopoietic regulation and leukemogenesis. Therefore,
these studies provide a framework on pathology for further eluci-
dating molecular mechanisms of critical lines of communication
between TET1 and TET2 in the pathogenesis of hematological
malignancies.EXPERIMENTAL PROCEDURES
Generation of Tet1 and Tet2 Conditional Knockout Mice
Tet2:flox allele mice were generated as follows: the targeting vector was con-
structed in a plasmid containing a Neo cassette flanked by two FRT sites.
A 0.8-kb genomic fragment containing the 11th exon of Tet2 (coding part of
the catalytic domain) was inserted between two loxP sites (cassette map:
loxP-exon11-loxP-FRT-Neo-FRT, Figure S4A). For gene targeting, 4.4-kb 50
and 3.6-kb 30 arm genomic fragments were subcloned into the vector. The
targeting vector was electroporated into 129/sv ES cells and subsequently
screened by Southern blot (Figure S4B). Two positive clones were selected
for the blastocyst injection. Male chimeric mice were crossed to C57BL/6
females to screen for germline transmission of Tet2:flox allele (Tet2f/+).
Tet2f/+micewere crossed to Flippase deleter mice to remove theNeo cassette
(Figure S4B) (Li et al., 2011; Wang et al., 2014). Tet1:flox allele mice were
generated from the previously reported Tet1+/H mESCs (Dawlaty et al., 2011)
as outlined in Figures S4C and S4D. Tet2f/f;MxCre, Tet1f/f;MxCre and Tet1f/f;
Tet2f/f;MxCremice were produced for studies. MxCre expression was inducedthors
by intraperitoneal injection of three doses of 300 mg of polyinosine-polycyto-
sine (pI:pC) (Figure S4E). Animal care was in accordance with institutional
guidelines and approved by the Institutional Animal Care and Use Committee
(IACUC), University of Miami Miller School of Medicine and Department of
Comparative Medicine, and Massachusetts Institute of Technology.
Bioinformatics and Statistical Analyses
hME-Seal was performed as described previously (Song et al., 2011). MeDIP
was performed according to the manufacturer’s protocol. Bioinformatics anal-
ysis for 5hmC-seq andMeDIP-seq were described previously (Szulwach et al.,
2011; Yao et al., 2014). Differences between experimental groups were deter-
mined by the Student’s t test or ANOVA followed by Newman-Keuls multiple
comparison tests as appropriate. p values <0.05 were considered significant.
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